Related references
Note: Only part of the references are listed.Impact of inflammation on vascular disease in hypertension
Agostino Virdis et al.
MATURITAS (2014)
Increased Plasma DPP4 Activity Is an Independent Predictor of the Onset of Metabolic Syndrome in Chinese over 4 Years: Result from the China National Diabetes and Metabolic Disorders Study
Fan Yang et al.
PLOS ONE (2014)
An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: Potential implications in cardiovascular disease
Jixin Zhong et al.
ATHEROSCLEROSIS (2013)
Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor
Yuji Ishibashi et al.
CARDIOVASCULAR DIABETOLOGY (2013)
An Update on Immune System Activation in the Pathogenesis of Hypertension
Michael J. Ryan
HYPERTENSION (2013)
Prevalence of Hypertension in China: A Cross-Sectional Study
Yun Gao et al.
PLOS ONE (2013)
Dipeptidyl peptidase-4: A key player in chronic liver disease
Minoru Itou et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2013)
Plasma dipeptidyl peptidase 4 activity correlates with body mass index and the plasma adiponectin concentration in healthy young people
Yasushi Kirino et al.
ENDOCRINE JOURNAL (2012)
Dipeptidyl Peptidase-4 Inhibition With Saxagliptin Enhanced Nitric Oxide Release and Reduced Blood Pressure and sICAM-1 Levels in Hypertensive Rats
R. Preston Mason et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2012)
Immune Mechanisms in Hypertension
Avshalom Leibowitz et al.
CURRENT HYPERTENSION REPORTS (2011)
Dipeptidyl Peptidase 4 Is a Novel Adipokine Potentially Linking Obesity to the Metabolic Syndrome
Daniela Lamers et al.
DIABETES (2011)
The role of oxidative stress in the pathophysiology of hypertension
Ramon Rodrigo et al.
HYPERTENSION RESEARCH (2011)
Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Decreases Systolic Blood Pressure in Japanese Hypertensive Patients with Type 2 Diabetes
Susumu Ogawa et al.
TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE (2011)
All-Cause Mortality Risk Among a National Sample of Individuals With Diabetes
Karin M. Nelson et al.
DIABETES CARE (2010)
Circulating levels of insulin-like growth factor-II/mannose-6-phosphate receptor in obesity and type 2 diabetes
Nilani Jeyaratnaganthan et al.
GROWTH HORMONE & IGF RESEARCH (2010)
Prevalence of Diabetes among Men and Women in China
Wenying Yang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Dipeptidyl Peptidase-4 (CD26): Knowing the Function before Inhibiting the Enzyme
E. Matteucci et al.
CURRENT MEDICINAL CHEMISTRY (2009)
Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial
M. Jadzinsky et al.
DIABETES OBESITY & METABOLISM (2009)
Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension
Goutam C. Mistry et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Soluble CD26/dipeptidyl peptidase IV enhances transendothelial migration via its interaction with mannose 6-phosphate/insulin-like growth factor II receptor
H Ikushima et al.
CELLULAR IMMUNOLOGY (2002)
Oxidative stress in arterial hypertension -: Role of NAD(P)H oxidase
G Zalba et al.
HYPERTENSION (2001)
Share Paper
